S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:MIST

Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis

$1.80
-0.01 (-0.55%)
(As of 03/27/2024 ET)
Today's Range
$1.75
$1.86
50-Day Range
$1.40
$2.20
52-Week Range
$1.33
$4.49
Volume
185,088 shs
Average Volume
520,533 shs
Market Capitalization
$60.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.20

Milestone Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
522.2% Upside
$11.20 Price Target
Short Interest
Healthy
1.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of Milestone Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.32) to ($1.72) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.28 out of 5 stars

Medical Sector

551st out of 939 stocks

Pharmaceutical Preparations Industry

255th out of 422 stocks

MIST stock logo

About Milestone Pharmaceuticals Stock (NASDAQ:MIST)

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

MIST Stock Price History

MIST Stock News Headlines

Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Milestone Pharma Shares Drop After Public Offering News
Milestone Pharmaceuticals Inc. (MIST)
See More Headlines
Receive MIST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MIST
Fax
N/A
Employees
39
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.20
High Stock Price Target
$25.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+522.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-59,690,000.00
Pretax Margin
-5,968.50%

Debt

Sales & Book Value

Annual Sales
$1 million
Book Value
$0.50 per share

Miscellaneous

Free Float
30,001,000
Market Cap
$60.26 million
Optionable
Optionable
Beta
1.77
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Joseph G. Oliveto M.B.A. (Age 56)
    CEO, President & Director
    Comp: $905.71k
  • Mr. Amit Hasija (Age 51)
    CFO & Executive VP of Corporate Development
    Comp: $603.18k
  • Dr. David B. Bharucha FACC (Age 62)
    M.D., Ph.D., Chief Medical Officer
    Comp: $440.67k
  • Dr. Philippe Douville M.B.A. (Age 62)
    Ph.D., Founder, Strategic Advisor & Member of Scientific Advisory Board
  • Mr. Jeff Nelson (Age 43)
    Chief Operating Officer
  • Ms. Kim Fox
    Vice President of Communications
  • Dr. Philip T. Sager FACC (Age 68)
    FAHA, FHRS, M.D., Chief Medical Advisor & Member of the Scientific Advisory Board
  • Dr. Guy Rousseau
    SVP of Regulatory Affairs and Quality Management
  • Ms. Anita Holz
    VP & Head of Medical Affairs

MIST Stock Analysis - Frequently Asked Questions

Should I buy or sell Milestone Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MIST shares.
View MIST analyst ratings
or view top-rated stocks.

What is Milestone Pharmaceuticals' stock price target for 2024?

5 brokers have issued 1-year price objectives for Milestone Pharmaceuticals' stock. Their MIST share price targets range from $4.00 to $25.00. On average, they anticipate the company's stock price to reach $11.20 in the next twelve months. This suggests a possible upside of 522.2% from the stock's current price.
View analysts price targets for MIST
or view top-rated stocks among Wall Street analysts.

How have MIST shares performed in 2024?

Milestone Pharmaceuticals' stock was trading at $1.67 at the beginning of the year. Since then, MIST stock has increased by 7.8% and is now trading at $1.80.
View the best growth stocks for 2024 here
.

When is Milestone Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our MIST earnings forecast
.

How were Milestone Pharmaceuticals' earnings last quarter?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced its quarterly earnings results on Friday, November, 12th. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.04.

What other stocks do shareholders of Milestone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), iBio (IBIO), Allena Pharmaceuticals (ALNA), Fulcrum Therapeutics (FULC), OPKO Health (OPK), VYNE Therapeutics (VYNE), Soleno Therapeutics (SLNO) and Agile Therapeutics (AGRX).

When did Milestone Pharmaceuticals IPO?

Milestone Pharmaceuticals (MIST) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Who are Milestone Pharmaceuticals' major shareholders?

Milestone Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (4.04%), Goldman Sachs Group Inc. (4.04%), BML Capital Management LLC (1.32%), Barclays PLC (0.76%), Dimensional Fund Advisors LP (0.22%) and Northern Trust Corp (0.10%). Insiders that own company stock include David Bharucha, Debra K Liebert, Paul F Truex, Robert James Wills and Rtw Investments, Lp.
View institutional ownership trends
.

How do I buy shares of Milestone Pharmaceuticals?

Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MIST) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners